Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
Samrat Pharmachem
|
JFL Life Sciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
36.01 % | 18.86 % | 12.26 % |
|
5yr average Equity Multiplier
|
-0.87 | 1.83 | 2.68 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 2.61 | 0.93 |
|
5yr Avg Net Profit Margin
|
0.0 | 3.87 % | 5.75 % |
|
Price to Book
|
2.46 | 0.92 | 1.56 |
|
P/E
|
14.92 | 0.0 | 13.61 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 58.79 Days | 138.58 Days |
|
Inventory Days
|
0.0 | 28.98 Days | 96.42 Days |
|
Days Receivable
|
0.0 | 80.32 Days | 135.23 Days |
|
Days Payable
|
0.0 | 46.76 Days | 103.44 Days |
|
5yr Average Interest Coverage Ratio
|
-1068.45 | 16.47 | 4.03 |
|
5yr Avg ROCE
|
21.53 % | 27.43 % | 17.72 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 5.58 % | 10.31 % |
|
5 yr average Debt to Equity
|
-1.45 | 0.21 | 0.9 |
|
5yr CAGR Net Profit
|
43.36 % | 5.93 % | 50.43 % |
|
5yr Average Return on Assets
|
-21.34 % | 10.3 % | 5.01 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 49.09 % | 67.47 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.45 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Samrat Pharmachem
|
JFL Life Sciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|